Back to top
more

Zoetis (ZTS)

(Delayed Data from NYSE)

$150.88 USD

150.88
3,565,640

+1.32 (0.88%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $150.87 -0.01 (-0.01%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).

Zoetis (ZTS) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

In the latest trading session, Zoetis (ZTS) closed at $145.54, marking a -0.66% move from the previous day.

Zoetis (ZTS) Stock Moves -0.14%: What You Should Know

by Zacks Equity Research

In the latest trading session, Zoetis (ZTS) closed at $149.77, marking a -0.14% move from the previous day.

Company News for Apr 15, 2024

by Zacks Equity Research

Companies In The Article Are:INTC,ZTS,X,NPSCY and PGR

Why Zoetis (ZTS) Dipped More Than Broader Market Today

by Zacks Equity Research

The latest trading day saw Zoetis (ZTS) settling at $165.69, representing a -0.1% change from its previous close.

Zoetis (ZTS) Down 4.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the VanEck Agribusiness ETF (MOO)?

by Zacks Equity Research

Sector ETF report for MOO

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

GRFS or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Company News for Feb 14, 2024

by Zacks Equity Research

Companies in The News Are: ZTS,MAR,ECL,HAS

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat

by Zacks Equity Research

Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.

Compared to Estimates, Zoetis (ZTS) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zoetis (ZTS) Q4 Earnings Lag Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of -6.77% and 1.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY

by Zacks Equity Research

Let's take a look at three biotech/drug companies, BIIB, ZTS, and INCY, slated to release quarterly results on Feb 13.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Ahead of Zoetis (ZTS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Zoetis (ZTS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GRFS or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GRFS vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

GRFS vs. ZTS: Which Stock Is the Better Value Option?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

GRFS or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. ZTS: Which Stock Is the Better Value Option?